SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced that it is initiating the first in a series of studies to evaluate the clinical utility of the NanoString Breast Cancer Intrinsic Subtyping Assay. The initial investigation will utilize samples from the TransATAC study to evaluate whether the assay, which is based on the PAM50 gene signature, can quantitate the probability of cancer recurrence in individual post-menopausal women with hormone receptor-positive, early stage breast cancer (ESBC) who have been treated with hormonal therapy.
